Versant Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Versant Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.9K	Buy	473 +255	+117%	+$7.53K	﹤0.01%	2079
2026 Q1	$5.4K	Buy	218 +205	+1,577%	+$4.88K	﹤0.01%	2357
2025 Q4	$303	Hold	13	–	–	﹤0.01%	2607
2025 Q3	$256	Hold	13	–	–	﹤0.01%	2598
2025 Q2	$282	Hold	13	–	–	﹤0.01%	2580
2025 Q1	$315	Hold	13	–	–	﹤0.01%	2442
2024 Q4	$271	Hold	13	–	–	﹤0.01%	2318
2024 Q3	$258	Hold	13	–	–	﹤0.01%	1944
2024 Q2	$201	Hold	13	–	–	﹤0.01%	1905
2024 Q1	$207	Hold	13	–	–	﹤0.01%	1828
2023 Q4	$219	Hold	13	–	–	﹤0.01%	1856
2023 Q3	$152	Hold	13	–	–	﹤0.01%	1899
2023 Q2	$175	Buy	+13	New	+$187	﹤0.01%	2001

Other funds holding CPRX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

LTAS

Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

EWM

Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return

OLA

Oliver Luxxe Assets Gladstone, New Jersey $680M AUM 47.51% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Versant Capital Management's CPRX Position: Q2 2026 in Review

Versant Capital Management increased its Catalyst Pharmaceutical (CPRX) stake by 117% in Q2 2026, buying an estimated $7.53K and bringing the position to 473 shares worth $14.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2079.

Versant Capital Management first reported a position in CPRX in Q2 2023 and has held it in 13 quarters since. 36 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Versant Capital Management held 473 shares of Catalyst Pharmaceutical worth $14.9K as of Q2 2026.
Versant Capital Management bought 255 Catalyst Pharmaceutical shares in Q2 2026, an estimated $7.53K.
Catalyst Pharmaceutical made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2079 holding.
Versant Capital Management first reported a position in Catalyst Pharmaceutical in Q2 2023 and has held it in 13 quarters since.
36 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.